Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lymphoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44380   clinical trials with a EudraCT protocol, of which   7392   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    Query did not match any clinical trials.
    These are paediatric studies completed by 26 January 2007, in respect of products authorised in the Community (Article 45 of the Paediatric Regulation (EC) No 1901/2006).
    Note: Advanced search filters for country, trial phase, gender, rare disease, IMP with orphan designation in the indication and age ranges of in-utero, adult or elderly do not apply to these records.
    1  2  3  4  5  6  7  8  9  Next»
    Study title: Yahalom.. Omitting radiotherapy after attaining FDG PET-negative status following chemotherapy alone for Hodgkin lymphoma: A randomized study caveat [yahalom-2007]Leuk Lymphoma. 2007 Sep;48(9):1667-9. Yahalom 2007
    Active substance: Steripet
    Study summary document link (including results): 2011-09 GE response Template List of published articles.doc
    View full study record
    Document reference: 48715
    Study title: LSA5 protocl for the treatment of advanced pediatric and adolescent non-hodgkin's lymphoma (NHL)
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21933
    Study title: NHL-BFM 90 : Efficacy of an ALL-type treatment with moderate-dose, prophylactic cranial irradiation and without local radiotherapy for childhood T-cell lymphobloastic lymphoma.
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21896
    Study title: Treatment for newly diagnosed patients with stage III/IV non-hodgkin lymphoma study XIII
    Active substance: ASPARAGINASE
    Study summary document link (including results):
    View full study record
    Document reference: 21932
    Study title: Non Hodgkin LymphomaNon Hodgkin Lymphoma
    Active substance: BLEOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 22796
    Study title: Kelly KM et al, Feasibility of upfront dose-intensive chemotherapy in children with, advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704, Ann Oncol. 2002;13 Suppl 1:107-11Kelly KM et al, Feasibility of upfront dose-intensive chemotherapy in children with, advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704, Ann Oncol. 2002;13 Suppl 1:107-11
    Active substance: BLEOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 22781
    Study title: Chow LM et al, Survival and late effects in children with Hodgkin's lymphoma treated with, MOPP/ABV and low-dose, extended-field irradiation, J Clin Oncol. 2006 Dec 20;24(36):5735-41Chow LM et al, Survival and late effects in children with Hodgkin's lymphoma treated with, MOPP/ABV and low-dose, extended-field irradiation, J Clin Oncol. 2006 Dec 20;24(36):5735-41
    Active substance: BLEOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 22774
    Study title: Hodgkin LymphomaHodgkin Lymphoma
    Active substance: BLEOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 22763
    Study title: T Cell LymphomaT Cell Lymphoma
    Active substance: BLEOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 22844
    Study title: van den Berg H et al, Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell, acute lymphoblastic leukemia, Med Pediatr Oncol. 1998 Jan;30(1):46-51. Erratum in: Med Pediatr Oncol 1998 May;30(5):318van den Berg H et al, Favorable outcome after 1-year treatment of childhood T-cell lymphoma/T-cell, acute lymphoblastic leukemia, Med Pediatr Oncol. 1998 Jan;30(1):46-51. Erratum in: Med Pediatr Oncol 1998 May;30(5):318
    Active substance: BLEOMYCIN
    Study summary document link (including results):
    View full study record
    Document reference: 22845
    Study title: Forns M et al, Results of the SHOP LNHB98 (LMB89) trial in pediatric patients with B-cell non-Hodgkin's lymphoma, Med Clin (Barc). 2007 May 5;128(17):641-6. Spanish
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26918
    Study title: Kelly KM et al Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704 Ann Oncol 2002;13 Suppl 1:107-11
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26770
    Study title: Seidemann K et al, Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Münster Group, J Clin Oncol. 2003 May 1;21(9):1782-9
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26914
    Study title: Seidemann K et al, Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90, Blood. 2001 Jun 15;97(12):3699-706
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26921
    Study title: Atra A et al, Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL)--results of the UKCCSG 9003 protocol, Br J Cancer. 1998 Jun;77(12):2281-5
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26871
    Study title: Kung FH et al, Ifosfamide/carboplatin/etoposide (ICE), an effective salvaging therapy for, recurrent malignant non-Hodgkin lymphoma of childhood: a Pediatric Oncology Group phase II study, Med Pediatr Oncol. 1999 Mar;32(3):225-6. No abstract available
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26923
    Study title: Reiter A et al, Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of, childhood: a prospective analysis of 62 patients enrolled in three consecutive, Berlin-Frankfurt-Munster group studies, J Clin Oncol. 1994 May;12(5):899-908
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26917
    Study title: Patte C et al, The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia, Blood. 2001 Jun 1;97(11):3370-9
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26892
    Study title: Cairo MS et al, Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report, Leukemia. 2002 Apr;16(4):594-600
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26920
    Study title: Cairo MS et al, Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and, adolescents, Blood. 2007 Apr 1;109(7):2736-43
    Active substance: ETOPOSIDE
    Study summary document link (including results):
    View full study record
    Document reference: 26875
    1  2  3  4  5  6  7  8  9  Next»
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Feb 12 12:48:16 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA